Celldex Therapeutics, Inc. (CLDX) · Peers
Celldex Therapeutics against the 15 other companies here in its SEC industry, In Vitro & In Vivo Diagnostic Substances. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 16, highest first.
Measure by measure
| Measure | CLDX | Peer median | Rank |
|---|---|---|---|
| Market value | $2.16B | median $136.69M | 4 of 16 |
| P/S | 13683.0× | median 4.2× | 1 of 16 |
| FCF yield | -11.2% | median -13.4% | 8 of 15 |
| ROE | -42.1% | median -26.8% | 8 of 12 |
| Revenue growth (4y, yearly) | -24.1% | median 11.1% | 15 of 15 |
| Current ratio | 11.8× | median 2.9× | 3 of 15 |
| Share count change | 3.1% | median 9.4% | 10 of 15 |
Green where Celldex Therapeutics is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.
The peers, largest first
| Company | Market value | P/E | ROIC | Score |
|---|---|---|---|---|
| CLDXCelldex Therapeutics, Inc. | $2.16B | P/E – | – | 2.9 |
| IDXXIDEXX Laboratories Inc | $44.15B | P/E 38.7× | 57.2% | 6.0 |
| LNTHLantheus Holdings, Inc. | $6.51B | P/E 23.6× | 18.5% | 6.2 |
| NEOGNeogen Corp | $2.58B | P/E – | -0.6% | 4.2 |
| NTLAIntellia Therapeutics, Inc. | $1.60B | P/E – | -115.4% | 3.6 |
| QDELQuidelOrtho Corp | $885.31M | P/E – | -13.8% | 3.2 |
| MYGNMyriad Genetics Inc | $380.69M | P/E – | -25.2% | 4.7 |
| TKNOAlpha Teknova, Inc. | $380.11M | P/E – | -21.4% | 4.1 |
| NNNNAnbio Biotechnology | $136.69M | P/E 21.3× | 25.0% | 5.6 |
| IMDXInsight Molecular Diagnostics Inc. | $98.50M | P/E – | – | 3.0 |
| ICCCImmucell Corp | $97.63M | P/E 25.9× | 9.8% | 5.9 |
| AWHLAspira Women's Health Inc. | $10.73M | P/E – | – | 4.0 |
| BMRABiomerica Inc | $8.49M | P/E – | -213.5% | 3.4 |
| CDIOCardio Diagnostics Holdings, Inc. | $5.00M | P/E – | -68.7% | 3.4 |
| QCLSQ/C Technologies, Inc. | $4.41M | P/E – | – | 7.5 |
| VNRXVolitionrx Ltd | $2.46M | P/E – | – | 4.1 |
The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.